Genmab - ADR Stock News

Company Announcement COPENHAGEN, Denmark; August 12, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 4,563 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others.

Genmab A/S (GMAB) Q2 2025 Earnings Conference Call August 7, 2025 12:00 PM ET Company Participants Anthony Pagano - Executive VP & CFO Brad Bailey - Corporate Participant Jan G.J. van de Winkel - Co-Founder, President & CEO Judith V.

August 7, 2025 Copenhagen, Denmark; Interim Report for the First Half Ended June 30, 2025 Highlights Epcoritamab a dvancing to earlier lines of therapy with the submission of a sBLA to the FDA for epcoritamab plus R 2 in patients with relapsed or refractory FL Rinatabart sesutecan (Rina-S ® ) continues to progress, demonstrating encouraging antitumor activity in endometrial cancer in data prese...

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced positive results of the Phase 3 EPCORE® FL-1 trial evaluating subcutaneous epcoritamab, a bispecific antibody, in combination with rituximab and lenalidomide (R2) versus R2 alone for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The study met its dual primary endpoints o...

Company Announcement COPENHAGEN, Denmark; August 7, 2025 Epcoritamab in combination with rituximab and lenalidomide (R 2 ) demonstrated statistically significant improvement in Overall Response Rate (ORR; 95.7%, p < 0.0001) and Progression-Free Survival (HR 0.21, p-value

Company Announcement Net sales of DARZALEX ® in the second quarter of 2025 totaled USD 3,539 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; July 16, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) prod...

Media Release COPENHAGEN, Denmark; July 1, 2025 Birgitte Stephensen, Executive Vice President and Chief Legal Officer to retire after 23 years with Genmab A/S Greg Mueller joins as new Executive Vice President, General Counsel and Chief Legal Officer, effective July 1 Genmab A/S (Nasdaq: GMAB ) a nnounced today that Birgitte Stephensen, Executive Vice President and Chief Legal Officer, will ret...

Company Announcement COPENHAGEN, Denmark; June 30, 2025 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on June 26, 2025. On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program.